Search

Your search keyword '"Tsai, Jo-Ting"' showing total 221 results
Start Over Author "Tsai, Jo-Ting"
221 results on '"Tsai, Jo-Ting"'

11. Predictive Value of the Interaction between CEA and Hemoglobin in Neoadjuvant CCRT Outcomes in Rectal Cancer Patients.

Author

Lai, Yi-Hsuan, Chang, Yu-Tien, Chang, Yu-Jia, Tsai, Jo-Ting, Li, Ming-Hsien, and Lin, Jang-Chun

Subjects
CANCER prognosis, RECTAL cancer, HEMOGLOBINS, CARCINOEMBRYONIC antigen, UNIVARIATE analysis
Abstract

The adoption of neoadjuvant concurrent chemoradiotherapy (CCRT) has reshaped the therapeutic landscape, but response prediction remains challenging. This study investigates the interaction between pre-CCRT carcinoembryonic antigen (CEA) and post-CCRT hemoglobin (Hb) levels in predicting the response of locally advanced rectal cancer (LARC) to CCRT. Retrospective data from 93 rectal cancer patients receiving neoadjuvant CCRT were analyzed. Univariate analyses assessed clinical factors associated with tumor regression grade (TRG) and T-stage outcomes. Machine learning identified predictive biomarkers. Interaction effects between CEA and Hb were explored through subgroup analyses. Post-CCRT Hb varied between pre-CCRT CEA groups. The interaction between pre-CCRT CEA and post-CCRT Hb influenced TRG. Males with normal pre-CCRT CEA and anemia showed better treatment responses. Females with elevated pre-CCRT CEA and post-CCRT anemia exhibited poorer responses. The interaction effect between them was significant, indicating that their relationship with TRG was not additive. Inflammatory biomarkers, WBC, neutrophil count, and post-CCRT platelet level correlated with CCRT response. Contrasting with previous findings, anemia was a predictor of better treatment response in males with normal pre-CCRT CEA. The interaction between pre-CCRT CEA and post-CCRT Hb levels predicts the response of LARC to CCRT. CEA, Hb, and sex should be considered when assessing treatment response. Inflammatory biomarkers contribute to response prediction. Understanding these complex relationships can enhance personalized treatment approaches in rectal cancer patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

12. Effectiveness of Stereotactic Ablative Radiotherapy for Systemic Therapy Respondents with Inoperable Pulmonary Oligometastases and Oligoprogression

Author

Ho, Chin-Beng, primary, Tsai, Jo-Ting, additional, Chen, Chun-You, additional, Shiah, Her-Shyong, additional, Chen, Hsuan-Yu, additional, Ting, Lai-Lei, additional, Kuo, Chia-Chun, additional, Lai, I-Chun, additional, Lai, Hsin-Yi, additional, Chung, Chi-Li, additional, Lee, Kai-Ling, additional, Tzeng, Huey-En, additional, Lee, Kuen-Haur, additional, Lee, Hsin-Lun, additional, Chen, Shang-Wen, additional, and Chiou, Jeng-Fong, additional

Published
2023
Full Text
View/download PDF

13. Compactness index: a radiosurgery outcome predictor for patients with unruptured brain arteriovenous malformations

Author

Huang, Po-Wei, primary, Peng, Syu-Jyun, additional, Pan, David Hung-Chi, additional, Yang, Huai-Che, additional, Tsai, Jo-Ting, additional, Shiau, Cheng-Ying, additional, Su, I-Chang, additional, Chen, Ching-Jen, additional, Wu, Hsiu-Mei, additional, Lin, Chung-Jung, additional, Chung, Wen-Yuh, additional, Guo, Wan-Yuo, additional, Lo, Wei-Lun, additional, Lai, Shao-Wen, additional, and Lee, Cheng-Chia, additional

Published
2023
Full Text
View/download PDF

15. Hypofractionated CyberKnife stereotactic radiosurgery for acoustic neuromas with and without association to neurofibromatosis Type 2

Author

Ju, D. T., Lin, J. W., Lin, M. S., Lee, L. M., Tseng, H. M., Wei, C. P., Yen, C. H., Hung, C. C., Hung, K. S., Lin, C. M., Lin, T. J., Chiu, W. T., Tsai, Jo-Ting, Steiger, H. -J., editor, Chiu, Wen-Ta, editor, Chiang, Yung-Hsiao, editor, Kao, Ming-Chien, editor, Hung, Ching-Chang, editor, Lin, Shinn-Zong, editor, Chen, Han-Jung, editor, Tang, Simon F. T., editor, and Hoffer, Barry J., editor

Published
2008
Full Text
View/download PDF

20. Tumor-Associated Macrophages Affect the Tumor Microenvironment and Radioresistance via the Upregulation of CXCL6/CXCR2 in Hepatocellular Carcinoma.

Author

Lee, Hsin-Lun, Tsai, Yi-Chieh, Pikatan, Narpati Wesa, Yeh, Chi-Tai, Yadav, Vijesh Kumar, Chen, Ming-Yao, and Tsai, Jo-Ting

Subjects
TUMOR microenvironment, LIVER cancer, SMALL interfering RNA, LIVER cells, MACROPHAGES
Abstract

Background: Hepatocellular carcinoma is the sixth most diagnosed malignancy and the fourth most common cause of cancer-related mortality globally. Despite progress in the treatment of liver cancer, nonsurgical treatments remain unsatisfactory, and only 15% of early-stage cases are surgically operable. Radiotherapy (RT) is a non-surgical treatment option for liver cancer when other traditional treatment methods are ineffective. However, RT has certain limitations, including eliciting poor therapeutic effects in patients with advanced and recurrent tumors. Tumor-associated macrophages (TAMs) are major inflammatory cells in the tumor microenvironment that are key to tumor development, angiogenesis, invasion, and metastasis, and they play an essential role in RT responses. Methods: We used big data analysis to determine the potential of targeting CXCL6/CXCR2. We enrolled 50 patients with liver cancer who received RT at our hospital. Tumor tissue samples were examined for any relationship between CXCL6/CXCR2 activity and patient prognosis. Using a cell coculture system (Transwell), we cocultured Huh7 liver cancer cells and THP-1 monocytes with and without CXCL6/CXCR2 small interfering RNA for 72 h. Results: The overexpression of CXCL6/CXCR2 was highly correlated with mortality. Our tissue study indicated a positive correlation between CXCL6/CXCR2 and M2-TAMs subsets. The coculture study demonstrated that THP-1 monocytes can secrete CXCL6, which acts on the CXCR2 receptor on the surface of Huh7 cells and activates IFN-g/p38 MAPK/NF-κB signals to promote the epithelial–mesenchymal transition and radio-resistance. Conclusions: Modulating the TAM/CXCL6/CXCR2 tumor immune signaling axis may be a new treatment strategy for the effective eradication of radiotherapy-resistant hepatocellular carcinoma cells. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

24. miR-671-5p Inhibition by MSI1 Promotes Glioblastoma Tumorigenesis via Radioresistance, Tumor Motility and Cancer Stem-like Cell Properties

Author

Lin, Jang-Chun, Kuo, Chun-Yuan, Tsai, Jo-Ting, and Liu, Wei-Hsiu

Subjects
radioresistance, glioblastoma multiforme, Musashi-1 (MSI1), QH301-705.5, miR-671-5p, Medicine (miscellaneous), Biology (General), Article, General Biochemistry, Genetics and Molecular Biology
Abstract

MicroRNAs (miRNAs) could be potential biomarkers for glioblastoma multiforme (GBM) prognosis and response to therapeutic agents. We previously demonstrated that the cancer stem cell marker Musashi-1 (MSI1) is an RNA binding protein that promotes radioresistance by increasing downstream RNA stability. To identify that MSI1 interacts with miRNAs and attenuates their function, we also get candidate miRNAs from the mRNA seq by predicting with TargetScan software. miR-671-5p in GBM cells interacts with MSI1 by intersecting the precipitated miRNAs with the predicted miRNAs. Notably, overexpression of MSI1 reversed the inhibitory effect of miR-671-5p. The phenotype of miR-671-5p in GBM cells could affect radiosensitivity by modulating the posttranscriptional activity of STAT3. In addition, miR-671-5p could attenuate tumor migration and cancer stem cell (CSC) characteristics by repressing the posttranscriptional activity of TRAF2. MSI1 may regulate GBM radioresistance, CSCs and tumor motility through miR-671-5p inhibition to increasing STAT3 and TRAF2 presentation. In vivo, the GBM tumor size was inversely correlated with miR-671-5p expression, but tumorigenesis was promoted by STAT3 and TRAF2 activation in the miR-671-5p-positive GBM population. miR-671-5p could be activated as a novel therapeutic target for GBM and has potential application as a predictive biomarker of glioblastoma prognosis.

Published
2021
Full Text
View/download PDF

27. PDK1 Inhibitor BX795 Improves Cisplatin and Radio-Efficacy in Oral Squamous Cell Carcinoma by Downregulating the PDK1/CD47/Akt-Mediated Glycolysis Signaling Pathway

Author

Pai, Shin, primary, Yadav, Vijesh Kumar, additional, Kuo, Kuang-Tai, additional, Pikatan, Narpati Wesa, additional, Lin, Chun-Shu, additional, Chien, Ming-Hsien, additional, Lee, Wei-Hwa, additional, Hsiao, Michael, additional, Chiu, Shao-Chih, additional, Yeh, Chi-Tai, additional, and Tsai, Jo-Ting, additional

Published
2021
Full Text
View/download PDF

36. EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases

Author

Lee Hsin-Lun, Chung Tao-Sang, Ting Lai-Lei, Tsai Jo-Ting, Chen Shang-Wen, Chiou Jeng-Fong, Leung Henry, and Liu H

Subjects
Epidermal growth factor receptor, Non-small cell lung cancer, Brain metastases, Radiotherapy, Medical physics. Medical radiology. Nuclear medicine, R895-920, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background The presence of epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) is associated with increased radiosensitivity in vitro. However, the results from clinical studies regarding the radiosensitivity in NSCLC with mutant EGFR are inconclusive. We retrospectively analyzed our NSCLC patients who had been regularly followed up by imaging studies after irradiation for brain metastases, and investigated the impact of EGFR mutations on radiotherapy (RT). Methods Forty-three patients with brain metastases treated with RT, together with EGFR mutation status, demographics, smoking history, performance status, recursive partitioning analysis (RPA) class, tumor characteristics, and treatment modalities, were included. Radiological images were taken at 1 to 3 months after RT, and 3 to 6 months thereafter. Radiographic response was evaluated by RECIST criteria version 1.1 according to the intracranial images before and after RT. Log-rank test and Cox regression model were used to correlate EGFR mutation status and other clinical features with intracranial radiological progression-free survival (RPFS) and overall survival (OS). Results The median follow-up duration was 15 months. Patients with mutant EGFR had higher response rates to brain RT than those with wild-type EGFR (80% vs. 46%; p = 0.037). Logistic regression analysis showed that EGFR mutation status is the only predictor for treatment response (p = 0.032). The median intracranial RPFS was 18 months (95% CI = 8.33-27.68 months). In Cox regression analysis, mutant EGFR (p = 0.025) and lower RPA class (p = 0.026) were associated with longer intracranial RPFS. EGFR mutation status (p = 0.061) and performance status (p = 0.076) had a trend to predict OS. Conclusions Mutant EGFR in NSCLC patients is an independent prognostic factor for better treatment response and longer intracranial RPFS following RT for brain metastases.

Published
2012
Full Text
View/download PDF

39. Astragalus polysaccharides (PG2) Enhances the M1 Polarization of Macrophages, Functional Maturation of Dendritic Cells, and T Cell-Mediated Anticancer Immune Responses in Patients with Lung Cancer

Author

Bamodu, Oluwaseun Adebayo, primary, Kuo, Kuang-Tai, additional, Wang, Chun-Hua, additional, Huang, Wen-Chien, additional, Wu, Alexander T.H., additional, Tsai, Jo-Ting, additional, Lee, Kang-Yun, additional, Yeh, Chi-Tai, additional, and Wang, Liang-Shun, additional

Published
2019
Full Text
View/download PDF

40. Astragalus polysaccharide (PG2) Ameliorates Cancer Symptom Clusters, as well as Improves Quality of Life in Patients with Metastatic Disease, through Modulation of the Inflammatory Cascade

Author

Huang, Wen-Chien, primary, Kuo, Kuang-Tai, additional, Bamodu, Oluwaseun Adebayo, additional, Lin, Yen-Kuang, additional, Wang, Chun-Hua, additional, Lee, Kang-Yun, additional, Wang, Liang-Shun, additional, Yeh, Chi-Tai, additional, and Tsai, Jo-Ting, additional

Published
2019
Full Text
View/download PDF

41. The Depletion of the “Don’t-Eat-Me” Signal CD47 Increases Radiosensitivity through Phenotypical Attenuation of Cancer Stem Cell and EMT Properties in Oral Squamous Cell Carcinoma Cells

Author

Pai, Shin, primary, Bamodu, Oluwaseun Adebayo, additional, Lin, Yen-Kuang, additional, Lin, Chun-Shu, additional, Chu, Pei-Yi, additional, Chien, Ming-Hsien, additional, Wang, Liang-Shun, additional, Hsiao, Michael, additional, Yeh, Chi-Tai, additional, and Tsai, Jo-Ting, additional

Published
2019
Full Text
View/download PDF

42. Karnofsky Performance Status as A Predictive Factor for Cancer-Related Fatigue Treatment with Astragalus Polysaccharides (PG2) Injection—A Double Blind, Multi-Center, Randomized Phase IV Study

Author

Wang, Cheng-Hsu, primary, Lin, Cheng-Yao, additional, Chen, Jen-Shi, additional, Ho, Ching-Liang, additional, Rau, Kun-Ming, additional, Tsai, Jo-Ting, additional, Chang, Cheng-Shyong, additional, Yeh, Su-Peng, additional, Cheng, Chieh-Fang, additional, and Lai, Yuen-Liang, additional

Published
2019
Full Text
View/download PDF

44. Prognostic and predictive factors for clinical and radiographic responses in patients with painful bone metastasis treated with magnetic resonance-guided focused ultrasound surgery

Author

Tsai, Yi-Chieh, primary, Lee, Hsin-Lun, additional, Kuo, Chia-Chun, additional, Chen, Chun-You, additional, Hsieh, Kevin Li-Chun, additional, Wu, Meng-Huang, additional, Wen, Yu-Ching, additional, Yu, Hsiao-Wei, additional, Hsu, Fang-Chi, additional, Tsai, Jo-Ting, additional, and Chiou, Jeng-Fong, additional

Published
2019
Full Text
View/download PDF

45. Effectiveness of stereotactic ablative radiotherapy in patients with advanced hepatocellular carcinoma unsuitable for transarterial chemoembolization

Author

Lee, Hsin-Lun, primary, Tsai, Jo-Ting, additional, Chen, Chun-You, additional, Lin, Ying-Chun, additional, Ho, Chin-Beng, additional, Ting, Lai-Lei, additional, Kuo, Chia-Chun, additional, Lai, I-Chun, additional, Lin, Chun-Yu, additional, Tang, Jui-Hsiang, additional, Huang, Yu-Min, additional, Kao, Wei-Yu, additional, Cheng, Sheng-Wei, additional, Shen, Chia-Ning, additional, Chen, Shang-Wen, additional, and Chiou, Jeng-Fong, additional

Published
2019
Full Text
View/download PDF

49. PG2 injection, a novel botanical drug approved for improving cancer-related fatigue among advanced cancer patients under standard palliative care: A double blind, multi-center, randomized phase IV study.

Author

Wang, Cheng-Hsu, primary, Lai, Yuen-Liang, additional, Lin, Cheng-Yao, additional, Chen, Jen-Shi, additional, Ho, Ching-Liang, additional, Rau, Kun-Ming, additional, Tsai, Jo-Ting, additional, Chang, Cheng-Shyong, additional, and Yeh, Su-Peng, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results